DARE-HPV1
Persistent High-Risk HPV Infection
Key Facts
Indication
Persistent High-Risk HPV Infection
Phase
Phase 2
Status
Active (IND Cleared)
Company
About Daré Bioscience
Daré Bioscience is a mission-driven biotech dedicated to closing the care gap in the historically underfunded field of women's health. Its strategy centers on developing and commercializing novel, often non-hormonal products through rigorous clinical development, with its first FDA-approved product, DARE to PLAY™ (Sildenafil Cream), now available via telehealth. The company's pipeline is broad, targeting key life stages from contraception to menopause, and is supported by strategic government funding, including a $10 million ARPA-H contract for its HPV program.
View full company profileTherapeutic Areas
Other Persistent High-Risk HPV Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| DARE-HPV | Dare Bioscience | Phase 2 |